Alnylam Pharmaceuticals Inc.

The hemophilia market is a challenging and competitive field but Sanofi is confident that fitusiran, which has just been given the green light by the US Food and Drug Administration (28 March), has th

Alnylam Pharmaceuticals’ Amvuttra (vitrisiran) will tap a substantially larger commercial opportunity with its US Food and Drug Administration approval for the treatment of ATTR with cardiomyopathy, b

Bayer has asked investors for patience as the conglomerate works its way through various challenges across its pharmaceuticals, crop science and consumer health businesses, and in 2024 pharma showed t

The disruption of existing markets is a dominant ambition of the nearly 20 applications expecting US Food and Drug Administration action in March. The Pink Sheet ’s US FDA Performance Tracker shows